Signal-transducing adaptor protein-2 modulates T-cell functions

Abstract

Immune responses are orchestrated by controlling the initiation, magnitude, and duration of various signaling pathways. Adaptor proteins act as positive or negative regulators by targeting critical molecules of signaling cascades. Signal-transducing adaptor protein-2 (STAP-2) contains typical features of adaptor proteins, like a pleckstrin homology (PH) domain in the N-terminal region and a Src homology 2 (SH2) domain in the central region. STAP-2 binds to a variety of signaling or transcriptional molecules to control multiple steps of inflammatory/immune responses. STAP-2 enhances T-cell receptor (TCR)-mediated signaling via the association with TCR-proximal CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs) and lymphocyte-specific protein tyrosine kinase (Lck). STAP-2 decreases adherence of T-cells to fibronectin (FN) through an association with focal adhesion kinase (Fak) and Casitas B-lineage Lymphoma (c-Cbl), and increases chemotaxis of T-cells toward stromal cell-derived factor-1α (SDF-1α) through interactions with Vav1 and Ras-related C3 botulinum toxin substrate 1 (Rac1). STAP-2 positively regulates activation-induced cell deathrough the association with Fas and caspase-8. This review describes the current knowledge of the roles of STAP-2 in T-cell-dependent immune responses and the possible clinical utility of STAP-2-targeting therapies.

Keywords

Signal-transducing adaptor protein / adaptor protein / signal transduction / T-cell / immune response / autoimmunity / chimeric antigen receptor T-cells

References

[1] Flynn DC. Adaptor proteins. Oncogene. 2001; 20: 6270-2.

[2] Luo LY, Hahn WC. Oncogenic signaling adaptor proteins. J Genet Genomics. 2015; 42: 521-9.

[3] Jordan MS, Singer AL, Koretzky GA. Adaptors as central mediators of signal transduction in immune cells. Nat Immunol. 2003; 4: 110-6.

[4] Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018; 18: 485-97.

[5] Minoguchi M, Minoguchi S, Aki D, Joo A, Yamamoto T, Yumioka T, et al. STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif*. J Biol Chem. 2003; 278: 11182-9.

[6] Ohya K, Kajigaya S, Kitanaka A, Yoshida K, Miyazato A, Yamashita Y, et al. Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. Proc Natl Acad Sci U S A. 1999; 96: 11976-81.

[7] Masuhara M, Nagao K, Nishikawa M, Sasaki M, Yoshimura A, Osawa M. Molecular cloning of murine STAP-1, the stem-cell-specific adaptor protein containing PH and SH2 domains. Biochem Biophys Res Commun. 2000; 268: 697-703.

[8] Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A, et al. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochem Biophys Res Commun. 2009; 384: 71-5.

[9] Ikeda O, Sekine Y, Mizushima A, Nakasuji M, Miyasaka Y, Yamamoto C, et al. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. J Biol Chem. 2010; 285: 38093-103.

[10] Sekine Y, Yamamoto T, Yumioka T, Sugiyama K, Tsuji S, Oritani K, et al. Physical and functional interactions between STAP-2/BKS and STAT5*. J Biol Chem. 2005; 280: 8188-96.

[11] Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, et al. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci. 2011; 102: 756-61.

[12] Yamamoto T, Yumioka T, Sekine Y, Sato N, Minoguchi M, Yoshimura A, et al. Regulation of FcεRI-mediated signaling by an adaptor protein STAP-2/BSK in rat basophilic leukemia RBL-2H3 cells. Biochem Biophys Res Commun. 2003; 306: 767-73.

[13] Sekine Y, Nishida K, Yamasaki S, Muromoto R, Kon S, Kashiwakura J, et al. Signal-transducing adaptor protein-2 controls the IgE-mediated, mast cell-mediated anaphylactic responses. J Immunol. 2014; 192: 3488-95.

[14] Ikeda O, Sekine Y, Kakisaka M, Tsuji S, Muromoto R, Ohbayashi N, et al. STAP-2 regulates c-Fms/M-CSF receptor signaling in murine macrophage Raw 264.7 cells. Biochem Biophys Res Commun. 2007; 358: 931-7.

[15] Ikeda O, Sekine Y, Muromoto R, Ohbayashi N, Yoshimura A, Matsuda T. Enhanced c-Fms/M-CSF receptor signaling and wound-healing process in bone marrow-derived macrophages of signal-transducing adaptor protein-2 (STAP-2) deficient mice. Biol Pharm Bull. 2008; 31: 1790-3.

[16] Sekine Y, Yumioka T, Yamamoto T, Muromoto R, Imoto S, Sugiyma K, et al. Modulation of TLR4 signaling by a novel adaptor protein signal-transducing adaptor protein-2 in macrophages. J Immunol. 2006; 176: 380-9.

[17] Saitoh K, Kashiwakura J, Kagohashi K, Sasaki Y, Kawahara S, Sekine Y, et al. STAP-2 is a novel positive regulator of TCR-proximal signals. J Immunol. 2022; 209: 57-68.

[18] Sekine Y, Tsuji S, Ikeda O, Sugiyma K, Oritani K, Shimoda K, et al. Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. J Immunol. 2007; 179: 2397-407.

[19] Sekine Y, Ikeda O, Tsuji S, Yamamoto C, Muromoto R, Nanbo A, et al. Signal-transducing adaptor protein-2 regulates stromal cell-derived factor-1α-induced chemotaxis in T cells. J Immunol. 2009; 183: 7966-74.

[20] Sekine Y, Yamamoto C, Kakisaka M, Muromoto R, Kon S, Ashitomi D, et al. Signal-transducing adaptor protein-2 modulates Fas-mediated T cell apoptosis by interacting with caspase-8. J Immunol. 2012; 188: 6194-204.

[21] Mitchell PJ, Sara EA, Crompton MR. A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene. 2000; 19: 4273-82.

[22] Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res. 2003; 13: 409-19.

[23] Stoecker K, Weigelt K, Ebert S, Karlstetter M, Walczak Y, Langmann T. Induction of STAP-1 promotes neurotoxic activation of microglia. Biochem Biophys Res Commun. 2009; 379: 121-6.

[24] Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia . Circ Res. 2014; 115: 552-5.

[25] Blanco-Vaca F, Martíƴn-Campos JM, Pérez A, Fuentes-Prior P . A rare STAP1 mutation incompletely associated with familial hypercholesterolemia . Clin Chim Acta. 2018; 487: 270-4.

[26] Lamiquiz-Moneo I, Restrepo-Córdoba MA, Mateo-Gallego R, Bea AM, del Pino Alberiche-Ruano M, Garcíƴa-Pavíƴa P, et al. Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia . Atherosclerosis. 2020; 292: 143-51.

[27] Loaiza N, Hartgers ML, Reeskamp LF, Balder JW, Rimbert A, Bazioti V, et al. Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (low-density lipoprotein) cholesterol in mice and humans . Arterioscler Thromb Vasc Biol. 2020; 40: 973-85.

[28] Kashiwakura J, Saitoh K, Ihara T, Sasaki Y, Kagohashi K, Enohara S, et al. Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells. PLoS One. 2020; 15: e0241440. Erratum in: PLoS One. 2021;16:e0250536.

[29] Toda J, Ichii M, Oritani K, Shibayama H, Tanimura A, Saito H, et al. Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML. Oncogene. 2020; 39: 5601-15.

[30] Matsuda T, Oritani K. STAP-2 adaptor protein regulates multiple steps of immune and inflammatory responses. Biol Pharm Bull. 2021; 44: 895-901.

[31] Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004; 23: 7990-8000.

[32] Weiss A. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell. 1993; 73: 209-12.

[33] Chan AC, Desai DM, Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol. 1994; 12: 555-92.

[34] Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, et al. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs . Nature. 1992; 356: 71-4.

[35] Sawasdikosol S, Chang JH, Pratt JC, Wolf G, Shoelson SE, Burakoff SJ. Tyrosine-phosphorylated Cbl binds to Crk after T cell activation. J Immunol. 1996; 157: 110-6.

[36] Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998; 92: 83-92.

[37] Motto DG, Ross SE, Wu J, Hendricks-Taylor LR, Koretzky GA. Implication of the GRB2-associated phosphoprotein SLP-76 in T cell receptor-mediated interleukin 2 production. J Exp Med. 1996; 183: 1937-43.

[38] Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997; 15: 707-47.

[39] Casas J, Brzostek J, Zarnitsyna VI, Hong J, Wei Q, Hoerter JAH, et al. Ligand-engaged TCR is triggered by Lck not associated with CD8 coreceptor. Nat Commun. 2014; 5: 5624.

[40] Jiang N, Huang J, Edwards LJ, Liu B, Zhang Y, Beal CD, et al. Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination. Immunity. 2011; 34: 13-23.

[41] Artyomov MN, Lis M, Devadas S, Davis MM, Chakraborty AK. CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery. Proc Natl Acad Sci U S A. 2010; 107: 16916-21.

[42] Williams GT, Williams WJ. Granulomatous inflammation——a review. J Clin Pathol. 1983; 36: 723-33.

[43] Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 2002; 40: 198-204.

[44] Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003; 361: 1111-8.

[45] Tanaka T, Yamamoto Y, Muromoto R, Ikeda O, Sekine Y, Grusby MJ, et al. PDLIM2 inhibits T helper 17 cell development and granulomatous inflammation through degradation of STAT3. Sci Signal. 2011; 4: ra85.

[46] Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006; 354: 942-55.

[47] Simmons SB, Pierson ER, Lee SY, Goverman JM. Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol. 2013; 34: 410-22.

[48] Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009; 9: 393-407.

[49] Dustin ML, Bivona TG, Philips MR. Membranes as messengers in T cell adhesion signaling. Nat Immunol. 2004; 5: 363-72.

[50] Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol. 2006; 27: 235-43.

[51] Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6: 56-68.

[52] Cary LA, Chang JF, Guan JL. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci. 1996; 109: 1787-94.

[53] Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996; 134: 793-9.

[54] Duan L, Reddi AL, Ghosh A, Dimri M, Band H. The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity. 2004; 21: 7-17.

[55] Mueller DL. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol. 2004; 5: 883-90.

[56] Hu J, Hubbard SR. Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins*. J Biol Chem. 2005; 280: 18943-9.

[57] Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000; 18: 217-42.

[58] Patrussi L, Baldari CT. Intracellular mediators of CXCR4-dependent signaling in T cells. Immunol Lett. 2008; 115: 75-82.

[59] Fernandis AZ, Prasad A, Band H, Klösel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene. 2004; 23: 157-67.

[60] Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996; 382: 635-8.

[61] Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol. 2000; 20: 1461-77.

[62] Okabe S, Fukuda S, Kim YJ, Niki M, Pelus LM, Ohyashiki K, et al. Stromal cell-derived factor-1α/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. Blood. 2005; 105: 474-80.

[63] Saitoh K, Tsuchiya T, Kashiwakura J, Muromoto R, Kitai Y, Sekine Y, et al. STAP-2 interacts with Pyk2 and enhances Pyk2 activity in T-cells. Biochem Biophys Res Commun. 2017; 488: 81-7.

[64] Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007; 7: 532-42.

[65] Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations . Immunol Today. 1995; 16: 39-43.

[66] Sekine Y, Yamamoto C, Ikeda O, Muromoto R, Nanbo A, Oritani K, et al. The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl. Biochem Biophys Res Commun. 2009; 384: 187-92.

[67] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11: 69.

[68] Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021; 21: 145-61.

[69] Bruzzoni-Giovanelli H, Alezra V, Wolff N, Dong CZ, Tuffery P, Rebollo A. Interfering peptides targeting protein-protein interactions: the next generation of drugs? Drug Discov Today. 2018; 23: 272-85.

[70] Yoshimaru T, Komatsu M, Matsuo T, Chen YA, Murakami Y, Mizuguchi K, et al. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun. 2013; 4: 2443.